皮里多斯蒂格改善了儿科肠道伪阻塞的食耐受性:单中心分析
Teresa Capriati1, Roberto De Giorgio2, Fabrizio Chiusolo3
1Gastroenterology and Nutritional Rehabilitation, "Bambino Gesù" Children's Hospital, IRCCS, Rome, Italy.
Journal of pediatric gastroenterology and nutrition
|August 4, 2025
概括
在儿科肠道伪阻塞 (PIPO) 患者中,Pyridostigmine改善了肠道营养耐受性和减少了对肠道营养的依赖性. 这种治疗也促进了生长,减少了住院治疗,为PIPO管理提供了有前途的选择.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 胃肠道运动障碍 胃肠道运动障碍
- 临床营养学 临床营养学
背景情况:
- 儿科肠道伪阻塞 (PIPO) 包含严重的动力障碍障碍,具有显著的死亡率和发病率.
- 目前的管理策略,包括营养支持,有局限性,突出未满足的临床需求.
- 催生剂可以改善口服养 (OF) 和肠道营养 (EN) 的耐受性,减少对肠道营养 (PN) 的依赖.
研究的目的:
- 为了评估pyridostigmine在改善肠道伪阻塞的儿科患者的营养结果和临床状况方面的疗效.
- 为了评估肠营养 (EN) 和肠营养 (PN) 的依赖性,生长参数和皮里多斯蒂格治疗后的临床事件的变化.
主要方法:
- 一组由10名儿科患者组成的队列,在6个月内不能容忍EN/OF,接受了pyridostigmine治疗.
- 营养结果 (通过EN/OF和PN摄入卡路里,增长) 在基线和6个月和12个月后被评估.
- 临床结果,包括住院和感染,在治疗前后12个月进行了比较.
主要成果:
- 皮里多斯蒂格明显著增加了EN/OF的耐受性,EN/OF的中位热量摄入量在12个月后增加了25%以上 (p=0.0156).
- 两名患者完全停止了PN,所有患者的生长都有所改善 (体重中位数z-score从-1.3增加到-0.9).
- 在治疗后的一年里,住院病例和与中枢线相关的血流感染减少了; 一名患者患有胸肌梗塞.
结论:
- 皮里多斯提格通过增强EN/OF耐受性和减少PN依赖性,有效支持PIPO的营养管理.
- 这些研究结果表明,pyridostigmine是一种可行的治疗选择,可以改善儿科肠道伪阻塞的结果.
- 需要进行进一步的临床试验,以在更大的PIPO队列中证实这些初步发现.
相关概念视频
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
617
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
617
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
287
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
287
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
402
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
402
Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
Gastrointestinal Motility Disorders
596
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
596
Depolarizing Blockers: Pharmocokinetics
383
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
383


